Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
4.3
¥ trillionWording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedNet SalesNot disclosed → Sales of strategic focus products: 2x fiscal 2025 levels
Operating profitNot disclosed → Core operating profit before R&D expenses: cumulative total of at least ¥4.3 trillion over the plan period
Operating profit marginNot disclosed → Core operating margin before R&D expenses: 50%
Only the target level is shown because the current level for comparison was not provided.Key initiatives
01Generate cash through strong profit growth
02Accelerate pipeline-driven growth
03Disciplined capital allocation
04Improve productivity across the company
Non-financial targetsIndicator Number of Phase III/pivotal trials initiated / Target value At least 10 / Timing By fiscal 2030, Indicator Number of Phase III/pivotal trials initiated / Target value At least 5 / Timing By fiscal 2027
Risks identified by the company
Changes in the business environment and revisions to applicable laws and regulations in the pharmaceutical market
Changes in Exchange Rates
Delays in launching new products
The possibility of failing to achieve the expected results from sales activities for new and existing products
The possibility of being unable to continuously create competitive new drugs
Infringement of intellectual property rights by third parties and other matters
| Item | Details |
|---|---|
| Plan name | Management Plan 2026 |
| Plan period | Fiscal years 2026–2030 |
| Progress against the plan | Formulated |
| Sales Target | Not disclosed → Sales of strategic focus products: 2x fiscal 2025 levels |
| Operating profit target | Not disclosed → Core operating profit before R&D expenses: cumulative total of at least ¥4.3 trillion over the plan period |
| Operating profit margin target | Not disclosed → Core operating margin before R&D expenses: 50% |
| Non-financial targets | Indicator Number of Phase III/pivotal trials initiated / Target value At least 10 / Timing By fiscal 2030, Indicator Number of Phase III/pivotal trials initiated / Target value At least 5 / Timing By fiscal 2027 |
| Key initiatives | Generate cash through strong profit growth, Accelerate pipeline-driven growth, Disciplined capital allocation, Improve productivity across the company |
| Risks identified | Changes in the business environment and revisions to applicable laws and regulations in the pharmaceutical market, Changes in Exchange Rates, Delays in launching new products, The possibility of failing to achieve the expected results from sales activities for new and existing products, The possibility of being unable to continuously create competitive new drugs, Infringement of intellectual property rights by third parties and other matters |
| Publication date | 26 May 2026 |
Items this document does not state (15)
Net income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Astellas Pharma Inc. has built the strong business foundation needed to achieve robust growth beyond 2030 and deliver greater "value" to patients faster. The company aims to achieve growth in areas with high unmet medical needs by capitalizing on the growth of its strategic focus products and its strong pipeline.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.